Adimmune Future Growth

Future criteria checks 0/6

Adimmune is forecast to grow revenue at 4.3% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth52.5%
Revenue growth rate4.3%
Future return on equity-0.3%
Analyst coverage

Low

Last updated04 Dec 2024

Recent future growth updates

Recent updates

Little Excitement Around Adimmune Corporation's (TWSE:4142) Revenues

Aug 13
Little Excitement Around Adimmune Corporation's (TWSE:4142) Revenues

Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High Quality

Apr 05
Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High Quality

Is Adimmune (TPE:4142) Using Debt In A Risky Way?

Mar 01
Is Adimmune (TPE:4142) Using Debt In A Risky Way?

Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three Years

Jan 07
Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three Years

Earnings and Revenue Growth Forecasts

TWSE:4142 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,775N/AN/A5851
12/31/20251,709N/AN/A-1,2731
12/31/20241,692N/AN/A1,5001
9/30/20241,571-608-363-89N/A
6/30/20241,657-608-262-75N/A
3/31/20241,659-575-184100N/A
12/31/20231,785-640-1,271-892N/A
9/30/20231,810-165-392-109N/A
6/30/20231,924-9-641-191N/A
3/31/20232,369277-823-437N/A
12/31/20222,252291-712-292N/A
9/30/20222,613525-549-321N/A
6/30/20222,279267-1,002-388N/A
3/31/20221,84058-1,149-383N/A
12/31/20211,79443-1,326-481N/A
9/30/20211,670989-1721,139N/A
6/30/20211,5349882471,230N/A
3/31/20211,5091,0085021,274N/A
12/31/20201,8691,2411,7682,322N/A
9/30/20201,675-21-253108N/A
6/30/20201,564-71-97149N/A
3/31/20201,607-101-5275N/A
12/31/20191,300-281-508-253N/A
9/30/20191,079-616-338-206N/A
6/30/2019887-733-256-159N/A
3/31/2019812-637-205-170N/A
12/31/2018822-618-646-602N/A
9/30/2018627-564-488-451N/A
6/30/2018538-670N/A-423N/A
3/31/2018558-742N/A-377N/A
12/31/2017563-760N/A7N/A
9/30/2017648-670N/A-289N/A
6/30/2017576-687N/A-390N/A
3/31/2017637-643N/A-427N/A
12/31/2016607-595N/A-774N/A
9/30/2016437-717N/A-678N/A
6/30/2016392-779N/A-538N/A
3/31/2016308-767N/A-531N/A
12/31/2015291-761N/A-374N/A
9/30/2015312-655N/A-585N/A
6/30/2015270-714N/A-391N/A
3/31/2015503-605N/A-246N/A
12/31/2014481-614N/A-417N/A
9/30/2014473-569N/A-430N/A
6/30/2014532-426N/A-430N/A
3/31/2014413-584N/A-568N/A
12/31/2013414-600N/A-517N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4142's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 4142's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4142's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 4142's revenue (4.3% per year) is forecast to grow slower than the TW market (12.2% per year).

High Growth Revenue: 4142's revenue (4.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4142 is forecast to be unprofitable in 3 years.


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:11
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adimmune Corporation is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jianzheng WuCapital Securities Corporation
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.
Hengyu FuMasterlink Securities Corp.